Open Access

Impact of SLC20A1 on the Wnt/β‑catenin signaling pathway in somatotroph adenomas

  • Authors:
    • Jianhua Li
    • Wei Dong
    • Zhenye Li
    • Hongyun Wang
    • Hua Gao
    • Yazhuo Zhang
  • View Affiliations

  • Published online on: August 6, 2019     https://doi.org/10.3892/mmr.2019.10555
  • Pages: 3276-3284
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Studies have revealed that genetic and functional aberrations of oncogenes, tumor‑suppressor genes, signaling pathways and receptors are among the most prominent events in pituitary tumorigenesis, and a potent biomarker would be helpful for early diagnosis, subsequent treatment and disease control. The present study investigated the expression signatures of solute carrier family 20 member 1, also known as phosphate transporter 1 (SLC20A1) and the Wnt/β‑catenin signaling pathway in 52 patients with somatotroph adenomas. According to immunohistochemistry analysis, the H‑score of SLC20A1 was 222.6±15.2 in invasive tumor samples and 144.5±30.4 in non‑invasive tumor samples (P<0.01), while the H‑scores of β‑catenin were 210.1±21.4 and 134.9±32.7, respectively (P<0.05). The H‑scores of Wnt inhibitory factor 1 (Wif1) exhibited the opposite trend, with scores of 134.5±22.7 and 253.6±14.8, respectively (P<0.01). The H‑scores of SLC20A1 were negatively associated with those of Wif1 in somatotroph adenomas (correlation coefficient r=‑0.367). The mean progression‑free survival in the low SLC20A1 group was longer than that in the group with high SLC20A1 H‑scores (P=0.024). Reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting confirmed the interference efficiency of the segments short hairpin (Sh)‑B‑SLC20A1 and Sh‑C‑SLC20A1. Cell proliferation experiments revealed that the cell viability of the Sh‑B‑SLC20A1 group was 76.3±4.5, 65.7±3.7 and 53.1±3.2% of that of control GH3 cells after 24, 48 and 72 h of transfection, respectively, while the cell viability of the Sh‑C‑SLC20A1 group was 86.4±5.7, 75.6±4.4 and 67.5±3.8%, respectively (P<0.05). ELISA analysis demonstrated the growth hormone (GH) levels in the Sh‑B‑SLC20A1 and Sh‑C‑SLC20A1 groups to be 34.7±10.4 and 54.6±14.4%, respectively, of that of control GH3 cells (P<0.05). The transmembrane invasion assay revealed that knocking down SLC20A1 significantly suppressed cell invasion in the Sh‑B‑SLC20A1 and Sh‑C‑SLC20A1 groups. RT‑qPCR and western blotting demonstrated that Sh‑B‑SLC20A1 and Sh‑C‑SLC20A1 evidently increased the levels of Wif1 and secreted frizzled‑related protein 4. The present data suggested that SLC20A1 levels are positively associated with tumor size, invasive behavior and tumor recurrence in somatotroph adenomas. Furthermore, SLC20A1 may be associated with the activation of the Wnt/β‑catenin signaling pathway.

References

1 

AlDallal S: Acromegaly: A challenging condition to diagnose. Int J Gen Med. 11:337–343. 2018. View Article : Google Scholar : PubMed/NCBI

2 

Inoshita N and Nishioka H: The 2017 WHO classification of pituitary adenoma: Overview and comments. Brain Tumor Pathol. 35:51–56. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CM, Pinedo AC, Guerrero DP, Barrera CA, Franco HI, Ribeiro-Oliveira A Jr, et al: Challenges in the diagnosis and management of acromegaly: A focus on comorbidities. Pituitary. 19:448–457. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Kempf J, Schmitz A, Meier A, Delfs N, Mueller B, Fandino J, Schuetz P and Berkmann S: Adenoma size and postoperative IGF-1 levels predict surgical outcomes in acromegaly patients: Results of the Swiss Pituitary Registry (SwissPit). Swiss Med Wkly. 148:w146532018.PubMed/NCBI

5 

Välimäki N, Demir H, Pitkänen E, Kaasinen E, Karppinen A, Kivipelto L, Schalin-Jäntti C, Aaltonen LA and Karhu A: Whole-genome sequencing of growth hormone (GH)-secreting pituitary adenomas. J Clin Endocrinol Metab. 100:3918–3927. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Picard C, Silvy M, Gerard C, Buffat C, Lavaque E, Figarella-Branger D, Dufour H, Gabert J, Beckers A, Brue T, et al: Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: Association with tumor size and response to pharmacologic treatment. Int J Cancer. 121:1245–1252. 2007. View Article : Google Scholar : PubMed/NCBI

7 

Forster IC, Hernando N, Biber J and Murer H: Phosphate transporters of the SLC20 and SLC34 families. Mol Aspects Med. 34:386–395. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Ravera S, Virkki LV, Murer H and Forster IC: Deciphering PiT transport kinetics and substrate specificity using electrophysiology and flux measurements. Am J Physiol Cell Physiol. 293:C606–C620. 2007. View Article : Google Scholar : PubMed/NCBI

9 

Byskov K, Jensen N, Kongsfelt IB, Wielsøe M, Pedersen LE, Haldrup C and Pedersen L: Regulation of cell proliferation and cell density by the inorganic phosphate transporter PiT-1. Cell Division. 7:72012. View Article : Google Scholar : PubMed/NCBI

10 

Kongsfelt IB, Byskov K, Pedersen LE and Pedersen L: High levels of the type III inorganic phosphate transporter PiT-1 (SLC20A1) can confer faster cell adhesion. Exp Cell Res. 326:57–67. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Sato K and Akimoto K: Expression levels of KMT2C and SLC20A1 identified by information-theoretical analysis are powerful prognostic biomarkers in ER-positive breast cancer. Clin Breast Cancer. 17:e135–e142. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Song W, Qian L, Jing G, Jie F, Xiaosong S, Chunhui L, Yangfang L, Guilin L, Gao H and Yazhuo Z: Aberrant expression of the sFRP and WIF1 genes in invasive non-functioning pituitary adenomas. Mol Cell Endocrinol. 474:168–175. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Ricardo VL, Robert YO, Gunter K and Juan R: WHO classification of tumours of endocrine organ. 4th. International agency for research on cancere; France, Lyon: pp. 19–23. 2018

15 

Liu C, Gao H, Cao L, Gui S, Liu Q, Li C, Li D, Gong L and Zhang Y: The role of FSCN1 in migration and invasion of pituitary adenomas. Mol Cell Endocrinol. 419:217–224. 2016. View Article : Google Scholar : PubMed/NCBI

16 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

17 

Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C and Merle P: Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs. J Hepatol. 59:1107–1117. 2013. View Article : Google Scholar : PubMed/NCBI

18 

Ueland T, Olarescu NC, Jørgensen AP, Otterdal K, Aukrust P, Godang K, Lekva T and Bollerslev J: Increased serum and bone matrix levels of the secreted Wnt antagonist DKK-1 in patients with growth hormone deficiency in response to growth hormone treatment. J Clin Endocrinol Metab. 100:736–743. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Hage M, Viengchareun S, Brunet E, Villa C, Pineau D, Bouligand J, Teglas JP, Adam C, Parker F, Lombès M, et al: Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas. J Clin Endocrinol Metab. 103:1929–1939. 2018. View Article : Google Scholar : PubMed/NCBI

20 

Caimari F and Korbonits M: Novel genetic causes of pituitary adenomas. Clin Cancer Res. 22:5030–5042. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Mete O and Lopes MB: Overview of the 2017 WHO Classification of pituitary tumors. Endocr Pathol. 28:228–243. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Park HH, Kim EH, Ku CR, Lee EJ and Kim SH: Outcomes of aggressive surgical resection in growth hormone-secreting pituitary adenomas with cavernous sinus invasion. World Neurosurg. 117:e280–e289. 2018. View Article : Google Scholar : PubMed/NCBI

23 

Wang J, Liu Q, Gao H, Wan D, Li C, Li Z and Zhang Y: EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway. Tumour Biol. 39:10104283177062032017. View Article : Google Scholar : PubMed/NCBI

24 

Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, García-Carbonero R, Grande E, Jimenez-Fonseca P, Marazuela M, et al: Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treat Rev. 70:209–222. 2018. View Article : Google Scholar : PubMed/NCBI

25 

Su Z, Cai L, Lu J, Li C, Gui S, Liu C, Wang C, Li Q, Zhuge Q and Zhang Y: Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell. Cancer Cell Int. 17:152017. View Article : Google Scholar : PubMed/NCBI

26 

Occhi G, Losa M, Albiger N, Trivellin G, Regazzo D, Scanarini M, Monteserin-Garcia JL, Fröhlich B, Ferasin S, Terreni MR, et al: The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. J Neuroendocrin. 23:641–649. 2011. View Article : Google Scholar

27 

Bergeron F, Sirois F and Mbikay M: ACTH secretion by mouse corticotroph AtT20 cells is negatively modulated by the intracellular level of 7B2. FEBS Lett. 512:259–262. 2002. View Article : Google Scholar : PubMed/NCBI

28 

Peng H, Fan J, Wu J, Lang J, Wang J, Liu H, Zhao S and Liao J: Silencing of HEPN1 is responsible for the aggressive biological behavior of pituitary somatotroph adenomas. Cell Physiol Biochem. 31:379–388. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI

30 

Salaün C, Leroy C, Rousseau A, Boitez V, Beck L and Friedlander G: Identification of a novel transport-independent function of PiT-1/SLC20A1 in the regulation of TNF-induced apoptosis. J Biol Chem. 285:34408–34418. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Wajant H, Pfizenmaier K and Scheurich P: Tumor necrosis factor signaling. Cell Death Differ. 10:45–65. 2003. View Article : Google Scholar : PubMed/NCBI

32 

Kavitha K, Kowshik J, Kishore TK, Baba AB and Nagini S: Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim Biophys Acta. 1830:4433–4444. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Liu C, Wu Y, Yu S, Bai J, Li C, Wu D and Zhang Y: Increased β-catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach. Mol Med Rep. 5:1793–1799. 2017. View Article : Google Scholar

34 

Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJ, Cook RJ, Little NS, Clifton-Bligh RJ, Robinson BG and McDonald KL: Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology. 149:1235–1242. 2008. View Article : Google Scholar : PubMed/NCBI

35 

Chambers TJ, Giles A, Brabant G and Davis JR: Wnt signalling in pituitary development and tumorigenesis. Endocr Relat Cancer. 20:R101–R111. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Vassallo I, Zinn P, Lai M, Rajakannu P, Hamou MF and Hegi ME: WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. Oncogene. 35:12–21. 2016. View Article : Google Scholar : PubMed/NCBI

37 

Wang Y, Sang A, Zhu M, Zhang G, Guan H, Ji M and Chen H: Tissue factor induces VEGF expression via activation of the Wnt/β-catenin signaling pathway in ARPE-19 cells. Mol Vis. 22:886–897. 2016.PubMed/NCBI

38 

Shan XS, Liu Q, Li ZY, Li CZ, Gao H and Zhang YZ: Epithelial-mesenchymal transition induced by SMAD4 activation in invasive growth hormone-secreting adenomas. Open Chem. 16:571–582. 2018. View Article : Google Scholar

Related Articles

Journal Cover

October 2019
Volume 20 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, J., Dong, W., Li, Z., Wang, H., Gao, H., & Zhang, Y. (2019). Impact of SLC20A1 on the Wnt/β‑catenin signaling pathway in somatotroph adenomas. Molecular Medicine Reports, 20, 3276-3284. https://doi.org/10.3892/mmr.2019.10555
MLA
Li, J., Dong, W., Li, Z., Wang, H., Gao, H., Zhang, Y."Impact of SLC20A1 on the Wnt/β‑catenin signaling pathway in somatotroph adenomas". Molecular Medicine Reports 20.4 (2019): 3276-3284.
Chicago
Li, J., Dong, W., Li, Z., Wang, H., Gao, H., Zhang, Y."Impact of SLC20A1 on the Wnt/β‑catenin signaling pathway in somatotroph adenomas". Molecular Medicine Reports 20, no. 4 (2019): 3276-3284. https://doi.org/10.3892/mmr.2019.10555